This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
| Feature | TRINOVA-1 |
|---|---|
| Condition | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer |
| Design | Randomized, parallel assignment, quadruple masking |
| Primary purpose | Treatment |
| Sponsor | Amgen |
| Study start | 2010-11 |
| Primary completion date | 2013-03 |
2. Clinical Question
Population
Patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Intervention
AMG 386 combined with weekly paclitaxel chemotherapy.
Comparator
AMG 386 placebo combined with weekly paclitaxel chemotherapy.
Primary question
Does AMG 386 plus weekly paclitaxel affect progression-free survival compared with placebo plus weekly paclitaxel?
3. Trial Design
Randomized
Quadruple masked
Parallel assignment
Two treatment arms
| Arm | Interventions |
|---|---|
| AMG 386 arm | AMG 386 (drug) with weekly paclitaxel chemotherapy |
| Placebo arm | AMG 386 placebo with weekly paclitaxel chemotherapy |
4. Endpoints
| Endpoint | Definition | Time Frame |
|---|---|---|
| Progression-Free Survival | Primary endpoint | 8 Months on average |
5. Planned Analysis
The registry identifies Progression-Free Survival as the primary endpoint with an average time frame of 8 months. Results have not been posted on ClinicalTrials.gov.
For a randomized oncology trial with a progression-free survival endpoint, the statistical analysis would typically evaluate the time from randomization until disease progression or death. Common approaches include Kaplan-Meier estimation of the progression-free survival distribution, comparison of randomized groups using a time-to-event test, and estimation of relative treatment effects using a survival regression model.
6. Statistical Methodology
Time-to-event analysis
Progression-free survival is a time-to-event endpoint. These analyses account for patients who have not experienced progression or death by their last assessment through censoring methods.
Randomized comparison
Randomization creates treatment groups intended to be comparable at baseline. The primary statistical comparison focuses on differences between randomized treatment assignments.
Survival model interpretation
When survival regression models are used, effect estimates summarize relative differences between groups while accounting for follow-up time and censoring.
7. Statistical Methods Explained
Why is progression-free survival analyzed differently from a simple response rate?
Progression-free survival includes both whether and when an event occurs. A time-to-event analysis uses information from follow-up duration and censoring.
Why does randomization matter?
Randomization reduces systematic differences between groups, allowing statistical comparisons to focus on the assigned intervention.
What does a Kaplan-Meier curve show?
A Kaplan-Meier estimate describes the proportion of patients remaining event-free over time while accounting for censored observations.
Why is censoring important?
Some participants may not have experienced progression or death at the time of analysis. Censoring allows their available follow-up information to contribute to the analysis.
8. Limitations
- The registry does not report primary endpoint results or statistical estimates.
- Baseline characteristics and subgroup analyses are not reported in the registry information available here.
- Safety results by treatment arm are not reported in the registry information available here.
- Details of multiplicity adjustment, interim analysis, missing-data methods, and statistical analysis plans are not reported.
9. Why This Trial Matters Statistically
| Concept | Application |
|---|---|
| Randomization | Comparison of AMG 386 and placebo treatment strategies |
| Time-to-event analysis | Progression-Free Survival endpoint |
| Censoring | Required for patients without observed events at analysis |
| Clinical trial design | Phase 3 parallel randomized masked study |